EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • February 2nd, 2022 • Brickell Biotech, Inc. • Biological products, (no disgnostic substances) • Delaware
This Exclusive License Agreement (this “Agreement”) is entered into as of February 2, 2022 (the “Effective Date”) by and between Carna Biosciences, Inc., a corporation organized under the laws of Japan (or, Nippon-koku) having a principal place of business at BMA 3F, 1-5-5, Minatojima-minamimachi, Chuo-ku, Kobe 650-0047, Japan (“Licensor”) and Brickell Biotech, Inc., a Delaware corporation having a principal place of business at 5777 Central Avenue, Suite 102, Boulder, Colorado, USA 80301 (“Licensee”). Licensor and Licensee are sometimes herein referred to individually as a “Party” and collectively as the “Parties”.
